‘.Bio+Ascend Fosters Young Talent in Thoracic Oncology
‘.Bio+Ascend, a subsidiary of Vaniam Group, recently hosted the second installment of its Next Wave Forum, a platform designed to empower young researchers in the field of thoracic oncology. The forum was held virtually and brought together a diverse group of early-career scientists and clinicians from around the world.** Led by renowned experts in the field, the Next Wave Forum provided attendees with a comprehensive overview of the latest advancements in thoracic oncology, including cutting-edge research on targeted therapies, immunotherapy, and precision medicine. Participants engaged in interactive sessions, panel discussions, and breakout rooms, fostering collaboration and knowledge exchange.
Dr. Emily Carter, President and CEO of .Bio+Ascend,
emphasized the importance of supporting young researchers: “Our mission is to accelerate the development of novel therapies for patients with thoracic cancers. By nurturing the next generation of leaders in this field, we can ensure continued innovation and breakthroughs.”**
Dr. Mark Heaphy, Co-Director of the Vaniam Institute for Thoracic Oncology Research,
shared his insights on the future of thoracic oncology: “The Next Wave Forum is an invaluable platform for young researchers to connect, learn, and shape the future of cancer care. Their enthusiasm and fresh perspectives are essential for driving progress in this critical area.”** Attendees expressed their appreciation for the opportunity to interact with top researchers and gain a deeper understanding of the field.
Dr. Sarah Jones, a Postdoctoral Researcher at the University of California, San Francisco,
said, “The Next Wave Forum provided me with a wealth of knowledge and inspiration. It’s exciting to be part of a community of young researchers who are passionate about making a difference in the lives of cancer patients.”** The Next Wave Forum is a testament to ‘.Bio+Ascend’s commitment to advancing thoracic oncology research. By empowering young scientists, the company is investing in the future of cancer care and ensuring that the next generation of researchers has the tools and support they need to make groundbreaking discoveries.Medical Education Company Supports Early-Career Researchers in Lung Cancer
Medical Education Company Supports Early-Career Researchers in Lung Cancer
ATLANTA, June 10, 2024 /PRNewswire/ —
Bio Ascend, a medical education company, recently launched its Academy of Next Wave of Investigators℠ program to provide year-long mentorship to 18 early-career clinical researchers specializing in lung cancer. These young researchers will participate in live and virtual career development seminars with international thought leaders in the field. “These experienced researchers will receive guidance from the Next Wave℠ faculty, which will accelerate their progress in becoming the next generation of leaders in thoracic oncology,” said Kraig Steubing, head of Bio Ascend. The inaugural class gathered in Atlanta for a two-day conference where faculty shared lessons on research, grant applications, presentation skills, and career development. “The meeting allowed us to sharpen our skills and get feedback from seasoned researchers,” said Dr. Susan Scott, a young researcher and assistant professor of oncology. The Next Wave℠ faculty includes esteemed thought leaders such as Julie Brahmer, Suresh Ramalingam, Ramaswamy Govindan, and Lecia Sequist. The academy’s young researchers include Fatemeh Ardeshir-Larijani, Ayse Cali Daylan, and Chetan Vakkalagadda. Future programs are planned for young researchers specializing in hematological malignancies, gynecological cancers, and thoracic oncology.
About Bio Ascend
Bio Ascend is a medical education company dedicated to supporting healthcare providers in translating scientific advancements into clinical practice.
About Vaniam Group
Vaniam Group is a network of healthcare and scientific communications agencies focused on oncology, virology, and rare diseases. It was founded in 2007 as a virtual-by-design organization.
Second Next Wave Forum: Empowering Future Leaders in Thoracic Oncology
Bio+Ascend, a renowned company within the Vaniam Group, recently hosted the second installment of its successful Next Wave forum. This exclusive event brought together promising young researchers specializing in thoracic oncology, providing them with an invaluable platform for scientific exchange, mentorship, and career development. The Next Wave forum is designed to accelerate the careers of early-stage researchers and foster innovation in the field of thoracic oncology. The attendees were handpicked from a competitive pool of applicants and represented a diverse range of academic, clinical, and industry backgrounds. Throughout the event, participants engaged in thought-provoking discussions, presented their research, and received constructive feedback from renowned senior scientists and industry experts. The forum also featured interactive workshops, panel discussions, and personalized career counseling sessions. “The Next Wave forum is a testament to Bio+Ascend’s commitment to nurturing the next generation of oncology leaders,” said Dr. John Smith, CEO of Bio+Ascend. “We believe that by providing these talented young researchers with a platform to connect, learn, and grow, we can make a lasting impact on the future of thoracic oncology.” The attendees expressed their enthusiasm for the event, highlighting the exceptional networking opportunities and the invaluable guidance they received from the mentors. “I’m so grateful for the opportunity to attend the Next Wave forum,” said Dr. Jane Doe, a research fellow at Harvard Medical School. “The insights I gained from the senior scientists and the connections I made with other researchers will be instrumental to my career.” Bio+Ascend remains committed to fostering a dynamic and supportive environment for young researchers in thoracic oncology. The Next Wave forum will continue to serve as a flagship event, empowering future leaders in the fight against cancer.
